Colorectal Cancer Incidence Increasing in Younger Adults
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Gastrointestinal Cancer
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Postsurgical ctDNA Levels May Predict Disease Recurrence in Colorectal Cancer
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
Triplet Combination for Biliary Tract Cancers Clears Phase 2 Trial
The addition of nab-paclitaxel to gemcitabine-cisplatin appeared to confer clinical benefit in patients with advanced biliary tract cancers.
Oral Aspirin Does Not Up FIT Test Sensitivity for ID’ing CRC
Administration of a single dose of oral aspirin prior to fecal immunochemical testing does not increase test sensitivity for detecting advanced colorectal neoplasms.
MRI Selects “Good Prognosis” Rectal Cancer Patients for Primary Surgery
Rectal cancer patients with good tumor prognosis according to magnetic resonance imaging criteria may not need preoperative chemoradiotherapy.
No OS Benefit of Immunotherapy Plus MEK Inhibitor for Patients With Microsatellite-Stable Metastatic Colorectal Cancer
RAS tumor status was not predictive of benefit from the combination of atezolizumab and cobimetinib compared with regorafenib.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Next post in General Oncology
